VERA: Vera Corp Price to Sales

Corporate company logo of Vera Therapeutics Inc (VERA)

The P/S multiple, which stands at 189.30, reflects the revenue valuation dynamics of Vera Therapeutics, Inc. (VERA), which utilizes manufacturing outsourcing to maintain flexibility. Exclusive antibody rights and lobbyist support create a powerful defensive moat. Meanwhile, access to capital depends on drug trials, necessitating strict liquidity management amid high R&D expenditures.

Vera Pharma - VERA P/S Multiple (period 11/07/2026 - 11/17/2026)

Analytical breakdowns for Vera Corp (VERA)

- stock price and consensus target price:
Summary company analytics:Vera Pharma, VERA
Finished products of Vera Pharma

The P/S ratio is calculated as the ratio of market capitalization to annual revenue, measuring the value of one dollar of sales within the share price. For Vera Therapeutics, Inc. (VERA), this metric reflects market expectations for future monopoly revenues following the completion of costly clinical trials, allowing the P/S multiple to distinguish justified business value growth from a speculative bubble.

Who Vera Therapeutics, Inc. competes with

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Cap to Sales Volume DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV - P/S Multiple|ABCL: Price-to-Revenue Ratio|Tourmaline Bio, Inc. (TRML) - Price-to-Revenue Ratio|Price to Sales precigen.com (PGEN)|PHAR (pharming.com) - P/S Multiple|NKTR (Nektar Therapeutics Inc.) - Market Cap to Sales Volume|P/S Multiple UPB|ZBIO - Price to Sales|P/S Multiple IMNM (immunome.com)|Gossamer Bio, Inc. - Price-to-Revenue Ratio|KalVista Pharmaceuticals, Inc. - P/S Multiple|SEPN (Septerna) - Market Cap to Revenue Ratio|Pieris Corp (PVLA) - Price-to-Revenue Ratio|SVRA - Price-to-Revenue Coefficient|RIGL (rigel.com) - P/S Multiple|Market Cap to Revenue Ratio ANAB (AnaptysBio, Inc.)|P/S Multiple ATXS|enGene Holdings Inc (ENGN) - Price-to-Revenue Multiple|P/S Multiple RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Price-to-Sales Ratio|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA: P/S Multiple|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple